DiaMedica Therapeutics Inc. (DMAC) — Financial statements
Income statement, balance sheet, and cash flow for DiaMedica Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 25↑29.2% | 19↑45.4% | 13↑67.2% | 8↓10.6% | 9 | |
| General & Administrative Expenses | 10↑31.7% | 7↓6.7% | 8↑31.4% | 6↑24.1% | 5 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.19↓1.5% | 0.20↑90.3% | 0.10 | 0.00 | |
| SG&A Expenses | 10↑28.3% | 8↓6.5% | 8↑32.4% | 6↑26.2% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 34↑28.9% | 27↑25.5% | 21↑51.9% | 14↑2.6% | 14 | |
| Total Costs & Expenses | 34↑28.9% | 27↑25.5% | 21↑51.9% | 14↑2.6% | 14 | |
| Operating Results | ||||||
| Operating Income | -34↓28.9% | -27↓25.5% | -21↓51.9% | -14↓2.6% | -14 | |
| Depreciation & Amortization | 0.04↑10.3% | 0.04↑30.0% | 0.03↑20.0% | 0.03↑4.2% | 0.02 | |
| EBITDA | -34↓28.9% | -27↓25.5% | -21↓52.0% | -14↓2.6% | -14 | |
| EBIT | -34↓28.9% | -27↓25.5% | -21↓51.9% | -14↓2.6% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 2 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 2 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↓26.8% | 2↑17.5% | 2↑446.5% | 0.35↑330.5% | 0.08 | |
| Income Before Tax | -33↓34.1% | -24↓26.2% | -19↓41.7% | -14↓0.6% | -14 | |
| Income Tax Expense | 0.03↓6.7% | 0.03↓30.2% | 0.04↑53.6% | 0.03↑0.0% | 0.03 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -33↓34.0% | -24↓26.1% | -19↓41.7% | -14↓0.6% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -33↓34.0% | -24↓26.1% | -19↓41.7% | -14↓0.6% | -14 | |
| Bottom-Line Net Income | -33↓34.0% | -24↓26.1% | -19↓41.7% | -14↓0.6% | -14 | |
| EPS (Basic) | -0.70↓16.7% | -0.60↑0.0% | -0.60↓15.4% | -0.52↑20.0% | -0.65 | |
| EPS (Diluted) | -0.70↓16.7% | -0.60↑0.0% | -0.60↓15.4% | -0.52↑20.0% | -0.65 | |
| Weighted Average Shares | 47↑16.3% | 40↑24.1% | 33↑23.2% | 26↑27.3% | 21 | |
| Weighted Average Diluted Shares | 47↑16.3% | 40↑24.1% | 33↑23.2% | 26↑27.3% | 21 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.